BrainStorm’s Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting

BrainStorm’s Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting

<0> BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)Adrian Harel, Ph.D., CEO+972-3-9236384 </0>

BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is proud to announce that its positive Phase I/II ALS clinical trial data was selected as the opening presentation of the prestigious Israel Neurological Association’s Annual Meeting, which will convene on December 12, 2012 in Jerusalem, Israel. The data, regarding the first 12 ALS patients in the trial, will be presented by Principal Investigator Dr. Dimitrios Karussis, MD, of the Neurology Department at Hadassah Medical Center in Jerusalem, Israel.

The trial, which was designed to evaluate the safety and tolerability of BrainStorm's proprietary NurOwn™ cell therapy (bone marrow-derived, autologous, differentiated mesenchymal stromal cells) is being conducted at the Hadassah Medical Center in Jerusalem, Israel. The data being presented is on the first group of patients, all of whom suffer from early stage or progressive ALS, also known as Lou Gehrig's disease. All patients enrolled were transplanted with NurOwn either intramuscularly or intrathecally.

NurOwn™ was granted Orphan Drug designation for ALS by the US Food and Drug Administration (FDA). BrainStorm is planning to expand its ALS clinical development to the United States in 2013, pending FDA approval. The Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS clinical trials at these institutions.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at .

Read more on